首页> Proceedings of the National Academy of Sciences of the United States of America> Second-generation IL-2 receptor-targeted diphtheria fusion toxin exhibits antitumor activity and synergy with anti-PD-1 in melanoma.

Second-generation IL-2 receptor-targeted diphtheria fusion toxin exhibits antitumor activity and synergy with anti-PD-1 in melanoma.

导出 OA

翻译打印收藏纠错

第一作者： Laurene S,Cheung

第一单位： Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21231.

作者： Laurene S,Cheung ^[1] ; Juan,Fu ^[2] ; Pankaj,Kumar ^[1] ; Amit,Kumar ^[1] ; Michael E,Urbanowski ^[1] ; Elizabeth A,Ihms ^[1] ; Sadiya,Parveen ^[1] ; C Korin,Bullen ^[1] ; Garrett J,Patrick ^[1] ; Robert,Harrison ^[3] ; John R,Murphy ^[4] ; Drew M,Pardoll ^[5] ; William R,Bishai ^[4]

作者单位： Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21231. ^[1] Bloomberg∼Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD 21231.;Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231. ^[2] Department of Psychology, Northeastern University, Boston, MA 02115. ^[3] Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21231; john.murphy@jhmi.edu dpardol1@jhmi.edu wbishai1@jhmi.edu. ^[4] Bloomberg∼Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD 21231; john.murphy@jhmi.edu dpardol1@jhmi.edu wbishai1@jhmi.edu.;Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231. ^[5]

关键词 Tregs cancer immunotherapy fusion toxin